Publications by authors named "Simone Edenhofer"

Claim this Profile
F
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow

Blood· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang

Blood· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
Jennifer Jeck, Rebecca Kassubek, Jan Coburger, Simone Edenhofer, Stefan S Schönsteiner

Ther Adv Neurol Disord· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.
Simone A Edenhofer, Stephan Stilgenbauer

J Oncol Pract· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.
Henriette Huber, Simone Edenhofer, Sven Estenfelder, Stephan Stilgenbauer

Onco Targets Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis